Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease-1

Copyright information:Taken from "Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease"BMC Neuroscience 2006;7():65-65.Published online 2 Oct 2006PMCID:PMC1609172. (B) Dot blot analysis of T40216 and T30923 activity on aggregation. The zero (0) hour control represents reactions that were stopped immediately after addition of the protein; 24-hour reactions carried out in the absence of the oligonucleotide and stopped after 24-hours of incubation; Congo red, level of aggregation 24 hours after addition of Congo Red (10 μM).